Pharmacokinetics of clomipramine in dogs following single-dose intravenous and oral administration

American Journal of Veterinary Research

Volumn 61, Issue 1, 2000, Pages 74-79

  King, Jonathan N ^a   Maurer, Max P ^b   Hotz, Rolf P ^b   Fisch, Roland D ^a  

^a NOVARTIS PHARMA AG   (Switzerland)

^b Research and Development   (Switzerland)

Author keywords

[No Author keywords available]

Indexed keywords

CLOMIPRAMINE;

ANIMAL EXPERIMENT; ANIMAL MODEL; AREA UNDER THE CURVE; ARTICLE; CONTROLLED STUDY; DOG; DRUG DETERMINATION; DRUG EFFECT; DRUG EFFICACY; DRUG ELIMINATION; DRUG HALF LIFE; GAS CHROMATOGRAPHY; NONHUMAN; ULTRAFILTRATION;

ANIMALIA; CANIS FAMILIARIS;

EID: 0033972723     PISSN: 00029645     EISSN: None     Source Type: Journal    
DOI: 10.2460/ajvr.2000.61.74     Document Type: Article

References (29)

1. Dodson LA, Bender FH, Barteaux JW. Review of clomipramine: an effective antiobsessional agent. Hosp Formula 1991;26;489-499.
2. Trimble MR. Worldwide use of clomipramine. J Clin Psychiatry 1990;51:51-54.
3. McTavish D, Benfield P. Clomipramine. An overview of its pharmacological properties and a review of its therapeutic use in obsessive compulsive disorder and panic disorder. Drugs 1990;39:136-153.
4. Benfield DP, Harries CM, Luscombe DK. Some pharmacological aspects of desmethylclomipramine. Postgrad Med J 1980;56:13-18.
5. Goldberger E, Rapoport JL. Canine acral lick dermatitis: response to the antiobsessional drug domipramine. J Am Anim Hosp Assoc 1991;27:179-182.
6. Rapoport JL, Ryland DH, Kriete M. Drug treatment of canine acral lick. An animal model of obsessive-compulsive disorder. Arch Gen Psychiatry 1992;49:517-521.
7. Simpson B, CLOCSA Study Group. Treatment of separation-related anxiety in dogs with clomipramine. Results from a multicentre, blinded, placebo controlled clinical trial, in Proceedings. Int Conf Vet Behav Med, 1997;143-154.
8. Faigle JW, Dieterle W. The metabolism and pharmacokinetics of clomipramine (Anafranil). J Int Med Res 1973;1:281-290.
9. Hewson CJ, Conlon PD, Luescher UA, et al. The pharmacokinetics of clomipramine and desmethylclomipramine in dogs: parameter estimates following a single oral dose and 28 consecutive daily oral doses of clomipramine. J Vet Pharmacol Ther 1998;21:214-222.
10. Sioufi A, Pommier F, Dubois JP. Simultaneous determination of clomipramine and its N-desmethyl metabolite in human whole blood by capillary gas chromatography with mass-selective detection. J Chromatogr 1988;428:71-80.
11. Dubois JP, Küng W, Theobald W, et al. Measurement of clomipramine, N-desmethyl-clomipramine, imipramine and dehydroimipramine in biological fluids by selective ion monitoring and pharmacokinetics of clomipramine. Clin Chem 1976;22:892-897.
12. Aronson JK, Dengler HJ, Dettli L et al. Standardization of symbols in clinical pharmacology. Eur J Clin Pharmacol 1988;35:1-7.
13. Fluehler H, Grieve AP, Mandallaz D, et al. Bayesian approach to bioequivalence assessment: an example. J Pharm Sci 1983;72:1178-1181.
14. Racine-Poon A, Grieve AP, Fluehler H, et al. A two-stage procedure for bioequivalence studies. Biometrics 1987;43:847-856.
15. Evans LEJ, Bett JHN, Cox JR, et al. The bioavailability of oral and parenteral chlorimipramine (Anafranil) Prog Neuropsychopharmacol 1980;4:293-302.
16. Balant-Gorgia AE, Gex-Fabry M, Balant LP. Clinical pharmacokinetics of clomipramine. Clin Pharmacokinet 1991;20:447-462.
17. Nagy A, Johansson R. The demethylation of imipramine and clomipramine as apparent from their plasma kinetics. Psychopharmacology (Berl) 1977;54:125-131.
18. Furlanut M, Benetello P, Spina E. Pharmacokinetic optimisation of tricyclic antidepressant therapy. Clin Pharmacokinet 1993;24:301-318.
19. King JN, Maurer MP, Altmann BO, et al. Pharmacokinetics of clomipramine in dogs following single-dose and repeated-dose oral administration. Am J Vet Res 2000;61:80-85.
20. Gibaldi M, Perrier D. Pharmacokinetics. 2nd ed. New York: Marcel Dekker, 1982;171.
21. Jones RB, Luscombe DK. Plasma level studies with clomipramine (Anafranil). J Int Med Res 1977;5:98-107.
22. Luscombe DK. Pharmacokinetics of clomipramine. Br J Clin Prac 1979;3:35-50.
23. Nielsen KK, Flinois JP, Beaune P, et al. The biotransformation of clomipramine in vitro, identification of the cytochrome P450s responsible for the separate metabolic pathways. J Pharmacol Exp Ther 1996;277:1659-1664.
24. Friedman E, Cooper TB. Pharmacokinetics of chlorimipramine and its demethylated metabolite in blood and brain regions of rats treated acutely and chronically with chlorimipramine. J Pharmacol Exp Ther 1983;225:387-390.
25. Martensson E, Axelsson R, Nyberg G, et al. Pharmacokinetic properties of antidepressant drugs amitriptyline, clomipramine and imipramine: a clinical study. Curr Ther Res 1984;36:228-238.
26. Bertilsson L, Braithwaite R, Tybring G, et al. Techniques for plasma protein binding of demethylchlorimipramine. Clin Pharmacol Ther 1979;26:265-271.
27. Sallee FR, Pollock BG, Perel JM, et al. Intravenous pulse loading of clomipramine in adolescents with depression. Psychopharmacol Bull 1984;25:114-118.
28. Gibaldi M, Perrier D. Pharmacokinetics. 2nd ed. New York: Marcel Dekker, 1982;332-336.
29. Harrison LI, Gibaldi M. Physiologically based pharmacokinetic model for digoxin disposition in dogs and its preliminary application to humans. J Pharm Sci 1977;66:1679-1683.